JP2012529506A5 - - Google Patents

Download PDF

Info

Publication number
JP2012529506A5
JP2012529506A5 JP2012514923A JP2012514923A JP2012529506A5 JP 2012529506 A5 JP2012529506 A5 JP 2012529506A5 JP 2012514923 A JP2012514923 A JP 2012514923A JP 2012514923 A JP2012514923 A JP 2012514923A JP 2012529506 A5 JP2012529506 A5 JP 2012529506A5
Authority
JP
Japan
Prior art keywords
composition
range
chitosan
composition according
negatively charged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012514923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012529506A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2010/050650 external-priority patent/WO2010144044A1/en
Publication of JP2012529506A publication Critical patent/JP2012529506A/ja
Publication of JP2012529506A5 publication Critical patent/JP2012529506A5/ja
Pending legal-status Critical Current

Links

JP2012514923A 2009-06-10 2010-06-10 粘膜炎治療用組成物の使用 Pending JP2012529506A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0950441 2009-06-10
SE0950441-6 2009-06-10
PCT/SE2010/050650 WO2010144044A1 (en) 2009-06-10 2010-06-10 Use of a composition for the treatment of mucositis

Publications (2)

Publication Number Publication Date
JP2012529506A JP2012529506A (ja) 2012-11-22
JP2012529506A5 true JP2012529506A5 (cg-RX-API-DMAC10.html) 2013-07-25

Family

ID=43309105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012514923A Pending JP2012529506A (ja) 2009-06-10 2010-06-10 粘膜炎治療用組成物の使用

Country Status (9)

Country Link
US (1) US8906883B2 (cg-RX-API-DMAC10.html)
EP (1) EP2440216A4 (cg-RX-API-DMAC10.html)
JP (1) JP2012529506A (cg-RX-API-DMAC10.html)
CN (1) CN102458419A (cg-RX-API-DMAC10.html)
AU (1) AU2010259284A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI1009741A2 (cg-RX-API-DMAC10.html)
CA (1) CA2763092A1 (cg-RX-API-DMAC10.html)
RU (1) RU2011152518A (cg-RX-API-DMAC10.html)
WO (1) WO2010144044A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773017T3 (es) 2010-04-06 2020-07-09 Synedgen Inc Derivados de quitosano para el tratamiento de mucositis o ulceración
US10022393B2 (en) 2012-09-20 2018-07-17 Synedgen, Inc. Methods for treatment or prevention of damage resulting from radiation, trauma or shock
WO2015022907A1 (ja) * 2013-08-13 2015-02-19 生化学工業株式会社 カチオン化キトサンを含有する医薬
US20160287626A1 (en) * 2013-10-22 2016-10-06 Cantex Pharmaceuticals, Inc. Methods of treating and preventing radiation damage
US20180228832A1 (en) * 2015-08-18 2018-08-16 Pharma Seeds Create, Llc Stomatological composition containing nsaid or heparin compound
WO2019211483A1 (en) * 2018-05-04 2019-11-07 Bonoss Medical Aktiebolag A composition for reduction of scar formation
CA3102284A1 (en) 2018-06-03 2019-12-12 Glycomira Therapeutics, Inc. Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and/or chemotherapy
WO2021216494A1 (en) * 2020-04-24 2021-10-28 Intact Therapeutics, Inc. Compositions and methods for treatment of gastrointestinal bleeding
EP3981505B1 (en) * 2020-10-12 2024-11-27 Gambro Lundia AB Membrane with immobilized anticoagulant and process for producing same
SE545090C2 (en) * 2021-03-17 2023-03-28 Labrida As A hydrogel comprising chitosan for use in prevention and treatment of periodontal and peri-implant disease
WO2023044132A2 (en) * 2021-09-17 2023-03-23 Shawn Walker Use of chitosan complexes or compositions to reduce infiltration of environmental factors into the brain

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402531L (sv) * 1994-07-19 1996-01-20 Medicarb Ab Sårläkningsmedel
SE9402529D0 (sv) * 1994-07-19 1994-07-19 Astra Ab Anti-adherensmedel
SE507028C2 (sv) * 1996-08-06 1998-03-16 Medicarb Ab Ny medicinsk användning
DK1997478T3 (da) * 2001-02-15 2013-12-09 Access Pharma Inc Flydende formuleringer til forebyggelse og behandling af slimhindesygdomme og -lidelser
AU2002249046A1 (en) * 2001-04-23 2002-11-05 Nucryst Pharmaceuticals Corp. Lubricious coatings for substrates
EP1539192A1 (en) * 2002-04-24 2005-06-15 Medicarb AB Composition and kit for the treatment of inflammatory bowel diseases
WO2004032843A2 (en) * 2002-10-07 2004-04-22 Orapharma, Inc. Mucoadhesive tetracycline formulations
US20060058390A1 (en) * 2004-09-14 2006-03-16 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
EP1838335A1 (en) 2005-01-19 2007-10-03 Bonoss Medical AB Growth factor composition
DE102006024831B4 (de) 2006-05-24 2008-03-27 Heraeus Quarzglas Gmbh & Co. Kg Verfahren zur Herstellung eines Halbzeugs aus synthetischem Quarzglas
WO2008060764A2 (en) 2006-10-05 2008-05-22 Drugtech Corporation Topical therapies for oral mucositis and other conditions

Similar Documents

Publication Publication Date Title
HRP20201578T1 (hr) Formulacija rnk za imunoterapiju
JP2012092110A5 (cg-RX-API-DMAC10.html)
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
NZ630560A (en) Pharmaceutical compositions for combination therapy
HK1203489A1 (en) Purinone compounds as kinase inhibitors
MX2017006335A (es) Composiciones en gel de oxido de metal quelado.
NZ595061A (en) Formulation comprising avermectin particles coated with a photo - protecting agent
IN2014MN02288A (cg-RX-API-DMAC10.html)
UA115677C2 (uk) ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ
RU2011152518A (ru) Применение композиции для лечения мукозита
BR112013025517A2 (pt) uso de 2,3-diidroimidazo[1,2-c]quinazolinas substituídas
MX2015008481A (es) Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a.
MX351975B (es) Composiciones y metodos para el tratamiento de infecciones y tumores.
JP2012036176A5 (cg-RX-API-DMAC10.html)
GB2555364A (en) Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and polyalkyleneimine
BR112014027971A2 (pt) dispositivos médicos revestidos incluindo um agente terapêutico insolúvel em água
EP3792280A3 (en) Anti-blys antibody
MX2013011971A (es) Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina.
CL2014002918A1 (es) Derivados de espiro[2.4]heptano puenteados fluorados; composicion farmaceutica y uso como agonistas del receptor de alx en el tratamiento de enfermedades inflamatorias, alergicas. cardiovasculares, entre otras.
SG10201803562YA (en) Amorphous magnesium-substituted calcium phosphate compositions and their uses
IL223175A0 (en) Tamarind seed polysaccharide for use in the treatment of inflammatory diseases
BR112015022084A2 (pt) composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol
JP2015044878A5 (cg-RX-API-DMAC10.html)
CL2013001445A1 (es) Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer.
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.